001482403 000__ 05724cam\\22005657a\4500
001482403 001__ 1482403
001482403 003__ OCoLC
001482403 005__ 20231128003334.0
001482403 006__ m\\\\\o\\d\\\\\\\\
001482403 007__ cr\un\nnnunnun
001482403 008__ 231014s2023\\\\si\\\\\\o\\\\\000\0\eng\d
001482403 019__ $$a1402246532
001482403 020__ $$a9789819923410$$q(electronic bk.)
001482403 020__ $$a9819923417$$q(electronic bk.)
001482403 020__ $$z9819923409
001482403 020__ $$z9789819923403
001482403 0247_ $$a10.1007/978-981-99-2341-0$$2doi
001482403 035__ $$aSP(OCoLC)1402818327
001482403 040__ $$aEBLCP$$beng$$cEBLCP$$dYDX$$dGW5XE$$dEBLCP$$dYDX$$dOCLCO$$dOCLCF
001482403 049__ $$aISEA
001482403 050_4 $$aRC280.U74$$bG85 2023
001482403 08204 $$a616.99461$$223/eng/20231024
001482403 24502 $$aA guide to management of urological cancers /$$cPrabhjot Singh, Brusabhanu Nayak, Sridhar Panaiyadiyan, editors.
001482403 260__ $$aSingapore :$$bSpringer,$$c2023.
001482403 300__ $$a1 online resource (364 p.)
001482403 500__ $$a5.2 Postoperative Predictive Models for Clinically Localized RCC
001482403 5050_ $$aIntro -- Foreword -- Foreword -- Foreword -- Preface -- Contents -- About the Editors -- Part I: Renal Cell Carcinoma -- 1: Diagnosis and Clinical Staging -- 1.1 Introduction -- 1.2 Diagnosis of Renal Cancer -- 1.2.1 Clinical Diagnosis of Renal Cancer -- 1.2.2 Paraneoplastic Syndromes -- 1.3 Imaging Diagnosis -- 1.4 Ultrasound -- 1.4.1 Contrast-Enhanced Ultrasound -- 1.5 Contrast-Enhanced Computerized Tomography (CECT) -- 1.6 Magnetic Resonance Imaging -- 1.7 FDG PET/CT -- 1.8 Renal Mass Biopsy -- 1.9 Staging of Renal Cell Cancer -- 1.10 Nephrometry Scores
001482403 5058_ $$a1.11 Grading of Renal Cell Carcinoma -- 1.12 Conclusions -- References -- 2: Pathology and Staging -- 2.1 Introduction -- 2.1.1 Genetic Susceptibility -- 2.2 Classification of Renal Carcinomas -- 2.2.1 Clear Cell RCC -- 2.2.2 Papillary RCC -- 2.2.3 Chromophobe RCC -- 2.2.4 Clear Cell Papillary Renal Cell Tumor -- 2.2.5 Eosinophilic Solid and Cystic RCC -- 2.2.6 Mucinous Tubular and Spindle Cell Renal Cell Carcinoma -- 2.2.7 Collecting Duct Carcinoma -- 2.2.8 Molecularly Defined Renal Cell Carcinomas -- 2.2.9 Proposed Entities in the New WHO Classification of Renal Carcinomas
001482403 5058_ $$a2.3 Immunohistochemistry -- 2.4 Pathologic Prognostic Factors -- 2.5 Pathologic Staging of Renal Carcinomas -- References -- 3: Management of Localized and Locally Advanced RCC -- 3.1 Introduction -- 3.2 Why Is It Essential to Differentiate Localized and Locally Advanced RCC? -- 3.3 TNM Staging of RCCs -- 3.4 Evaluation of Renal Mass -- 3.5 Management -- 3.6 Role of Renal Biopsy -- 3.7 Role of Genetic Testing in RCC -- 3.8 Role of Lymphadenectomy -- 3.9 Renal Mass with Inferior Vena Caval Thrombus (IVCT) -- 3.10 Role of Neoadjuvant/Adjuvant Therapy LA-RCC
001482403 5058_ $$a3.11 Is There a Role of Downsizing the Tumour Before Surgery with These Agents? -- 3.12 Therapeutic Approaches Other Than Surgery -- References -- 4: Management of Metastatic Renal Cell Carcinoma -- 4.1 Introduction -- 4.2 Prognostic Models for Metastatic Disease -- 4.3 Cytoreductive Nephrectomy -- 4.4 First-Line Treatment for Metastatic ccRCC -- 4.4.1 Combination of VEGF-TKI Plus ICI -- 4.4.1.1 Axitinib + Pembrolizumab -- 4.4.1.2 Cabozantinib + Nivolumab -- 4.4.1.3 Lenvatinib + Pembrolizumab -- 4.4.1.4 Axitinib + Avelumab -- 4.4.2 Dual Checkpoint Inhibitors
001482403 5058_ $$a4.4.2.1 Ipilimumab + Nivolumab -- 4.4.3 VEGF-TKI Monotherapy -- 4.4.3.1 Cabozantinib -- 4.4.3.2 Sunitinib -- 4.4.3.3 Pazopanib -- 4.4.3.4 Cytokine Therapy -- 4.4.3.5 Surveillance -- 4.5 Second and Subsequent Lines of Therapy for Metastatic ccRCC -- 4.5.1 Axitinib -- 4.5.2 Cabozantinib -- 4.5.3 Lenvatinib + Everolimus -- 4.5.4 Nivolumab -- 4.5.5 Tivozanib -- 4.5.6 Belzutifan -- 4.6 Therapy for Metastatic Nonclear Cell RCC (nccRCC) -- 4.7 Conclusion -- References -- 5: Adjuvant Treatment and Follow-Up of Clinically Localized Renal Cell Carcinoma -- 5.1 Introduction
001482403 506__ $$aAccess limited to authorized users.
001482403 520__ $$aThe book provides comprehensive review of common uro-oncology cases mainly focusing on its management aspect. It includes diagnosis and clinical staging, surgical management, pathological staging, adjuvant treatment and follow up. It provides current evidence-based approaches for the management of common urological malignancies. All the chapters are written uniformly in a simple yet informative manner by experts in their respective fields. It contains well-prepared illustrations, relevant clinical images and flowcharts. The book is helpful for practicing urologists, uro-oncologists, oncologists as well as urology trainees, uro-oncology fellows in providing a holistic approach to cancer patients. It helps them to develop critical thinking and encourage discussion toward improving the overall care of the patients.
001482403 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed October 24, 2023).
001482403 650_0 $$aUrinary organs$$xCancer$$xTreatment.
001482403 650_0 $$aUrinary organs$$xCancer$$xDiagnosis.
001482403 650_6 $$aAppareil urinaire$$xCancer$$xTraitement.
001482403 655_0 $$aElectronic books.
001482403 7001_ $$aSingh, Prabhjot.
001482403 7001_ $$aNayak, Brusabhanu.
001482403 7001_ $$aPanaiyadiyan, Sridhar.
001482403 77608 $$iPrint version:$$aSingh, Prabhjot$$tA Guide to Management of Urological Cancers$$dSingapore : Springer,c2023$$z9789819923403
001482403 852__ $$bebk
001482403 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-981-99-2341-0$$zOnline Access$$91397441.1
001482403 909CO $$ooai:library.usi.edu:1482403$$pGLOBAL_SET
001482403 980__ $$aBIB
001482403 980__ $$aEBOOK
001482403 982__ $$aEbook
001482403 983__ $$aOnline
001482403 994__ $$a92$$bISE